- Home
- GVA vs RYTM Comparison
GVA vs RYTM Comparison
Compare GVA & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GVA
- RYTM
- Stock Information
- Founded
- GVA 1922
- RYTM 2008
- Country
- GVA United States
- RYTM United States
- Employees
- GVA N/A
- RYTM N/A
- Industry
- GVA Military/Government/Technical
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- GVA Industrials
- RYTM Health Care
- Exchange
- GVA Nasdaq
- RYTM Nasdaq
- Market Cap
- GVA 3.8B
- RYTM 3.8B
- IPO Year
- GVA 1990
- RYTM 2017
- Fundamental
- Price
- GVA $88.28
- RYTM $63.66
- Analyst Decision
- GVA Strong Sell
- RYTM Strong Buy
- Analyst Count
- GVA 1
- RYTM 12
- Target Price
- GVA $76.00
- RYTM $76.75
- AVG Volume (30 Days)
- GVA 556.5K
- RYTM 618.8K
- Earning Date
- GVA 07-31-2025
- RYTM 05-07-2025
- Dividend Yield
- GVA 0.59%
- RYTM N/A
- EPS Growth
- GVA 218.05
- RYTM N/A
- EPS
- GVA 2.58
- RYTM N/A
- Revenue
- GVA $4,034,846,000.00
- RYTM $136,863,000.00
- Revenue This Year
- GVA $7.95
- RYTM $37.88
- Revenue Next Year
- GVA $6.03
- RYTM $72.84
- P/E Ratio
- GVA $34.22
- RYTM N/A
- Revenue Growth
- GVA 11.42
- RYTM 48.88
- 52 Week Low
- GVA $58.23
- RYTM $36.27
- 52 Week High
- GVA $105.20
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- GVA 61.46
- RYTM 56.95
- Support Level
- GVA $84.45
- RYTM $58.72
- Resistance Level
- GVA $91.99
- RYTM $63.24
- Average True Range (ATR)
- GVA 1.81
- RYTM 2.49
- MACD
- GVA 0.06
- RYTM 0.03
- Stochastic Oscillator
- GVA 50.80
- RYTM 90.86
About GVA Granite Construction Incorporated
Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. It focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges, and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, with the remainder derived from its Materials segment.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.